Back Pain Archives - PharmaLive

U.S. FDA authorizes virtual reality system for reducing back pain

Approvals, Back Pain, Business, FDA/Regulatory, Virtual Reality

The U.S. Food and Drug Administration on November 16 authorized a virtual reality system from Applied VR for reducing lower back pain after a majority of patients in a trial testing the device showed lesser discomfort.

November 16, 2021/by Reuters Health

Novartis’ Cosentyx receives FDA approval for new indication

Approvals, Back Pain, Blockbusters, FDA, FDA/Regulatory, New Indications, Non-Radiographic Axial Spondyloarthritis (nr-axSpA), Spine, Therapeutics

The U.S. Food and Drug Administration approved Novartis’ Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis.

June 16, 2020/by GlobeNewswire

Nektar withdraws application for opioid painkiller after FDA panel’s vote

Addictions, Chronic Lower Back Pain (cLBP), FDA, FDA/Regulatory, Not Recommended For Approval, Opioids, Painkillers

Nektar Therapeutics withdrew the application for the company’s opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration panel unanimously voted against the drug’s approval.

January 14, 2020/by Reuters Health

Nektar Forms New Subsidiary

Business, Chronic Lower Back Pain (cLBP), Company Launches, FDA, New Drug Applications, Opioids, Pain, PDUFA

With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.

May 24, 2019/by BioSpace

Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Chronic Lower Back Pain (cLBP), Chronic Pain, Monoclonal Antibodies, Osteoarthritis

Pfizer Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

June 13, 2017/by Business Wire